Zydus Wellness

INR
387.60
-4.75 (-1.21%)
BSENSE

Feb 06

BSE+NSE Vol: 1.59 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.59 lacs (-60.07%) Volume

Shareholding (Dec 2025)

FII

3.27%

Held by 113 FIIs

DII

0.09%

Held by 27 DIIs

Promoter

69.63%

how big is Zydus Wellness?

06-Jun-2025

As of Jun 06, Zydus Wellness Ltd has a market capitalization of 12,364.68 Cr, with net sales of 2708.90 Cr and a net profit of 346.90 Cr for the latest four quarters.

Market Cap: Zydus Wellness Ltd has a market capitalization of 12,364.68 Cr and is classified as a Mid Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Zydus Wellness reported net sales of 2708.90 Cr and a net profit of 346.90 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: The balance sheet data is consolidated for the latest annual period ending in Mar'24. Shareholder's funds are reported at 5,357.50 Cr, and total assets amount to 5,992.10 Cr.

View full answer

Who are in the management team of Zydus Wellness?

06-Jun-2025

As of March 2023, the management team of Zydus Wellness includes Tarun Arora (CEO), Sharvil P Patel (Chairman), and several non-executive and independent directors, overseeing the company's operations and strategic direction.

As of March 2023, the management team of Zydus Wellness includes the following members:<BR><BR>1. Ganesh N Nayak - Non-Executive & Non-Independent Director<BR>2. Sharvil P Patel - Chairman (Non-Executive)<BR>3. Tarun Arora - Whole Time Director & CEO<BR>4. Kulin S Lalbhai - Non-Executive & Independent Director<BR>5. Ashish Bhargava - Nominee<BR>6. Dharmishta N Rawal - Non-Executive & Independent Director<BR>7. Srivishnu Raju Nandyala - Non-Executive & Independent Director<BR>8. Nandish P. Joshi - Company Secretary & Compliance Officer<BR>9. Akhil A. Monappa - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

View full answer

Has Zydus Wellness declared dividend?

06-Jun-2025

Zydus Wellness Ltd has declared a 50% dividend, amounting to ₹5 per share, with an ex-date of July 19, 2024. The dividend yield is 0.26%, and total returns over the past five years stand at 51.68%.

Zydus Wellness Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 5<BR>- Ex-date: 19 Jul 24<BR><BR>Dividend Yield: 0.26%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.86%, the dividend return was 0%, resulting in a total return of -4.86%.<BR><BR>Over the past year, the price return was 3.51%, the dividend return was 0.26%, leading to a total return of 3.77%.<BR><BR>In the 2-year period, the price return was 28.84%, the dividend return was 0.67%, culminating in a total return of 29.51%.<BR><BR>For the 3-year period, the price return was 23.44%, the dividend return was 0.97%, resulting in a total return of 24.41%.<BR><BR>In the last 4 years, the price return was -7.19%, the dividend return was 0.96%, leading to a total return of -6.23%.<BR><BR>Over the past 5 years, the price return was 50.14%, the dividend return was 1.54%, resulting in a total return of 51.68%.<BR><BR>Overall, Zydus Wellness has declared a dividend, which contributes to a modest dividend yield. The total returns over various periods show a mix of positive and negative performance, with the 5-year period reflecting the strongest total return.

View full answer

Who are the peers of the Zydus Wellness?

03-Jun-2025

Zydus Wellness peers include Hind. Unilever, ITC, Nestle India, Britannia Inds., and others, with average management risk and below-average growth. Its 1-year return is 14.09%, higher than Honasa Consumer's -32.21% but lower than Manorama Indust.'s 129.10%.

Peers: The peers of Zydus Wellness are Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, CCL Products, Avanti Feeds, Honasa Consumer, Mrs Bectors, and Manorama Indust.<BR><BR>Quality Snapshot: Excellent management risk is observed at ITC, Nestle India, and Britannia Inds., while Good management risk is found at Hind. Unilever, Godrej Consumer, CCL Products, Avanti Feeds, and Mrs Bectors. Average management risk is present at Zydus Wellness and Honasa Consumer. All peers exhibit Below Average growth except for Manorama Indust., which shows Excellent growth, while Zydus Wellness, Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, CCL Products, Avanti Feeds, Honasa Consumer, and Mrs Bectors show Below Average growth. Excellent capital structure is noted for ITC, Nestle India, Britannia Inds., Godrej Consumer, Zydus Wellness, Avanti Feeds, and Mrs Bectors, while CCL Products has Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Manorama Indust. at 129.10%, while the lowest is Honasa Consumer at -32.21%. Zydus Wellness has a 1-year return of 14.09%, which is significantly higher than Honasa Consumer but lower than Manorama Indust. Additionally, the six-month returns for Honasa Consumer and Mrs Bectors are negative.

View full answer

What does Zydus Wellness do?

17-Jul-2025

Zydus Wellness Ltd is a Mid Cap FMCG company specializing in health and wellness products, with reported net sales of ₹9,131 Cr and a net profit of ₹1,719 Cr for the quarter ending March 2025. The company has a market cap of ₹12,843 Cr and key metrics include a P/E ratio of 37.00 and a dividend yield of 0.55%.

Overview:<BR>Zydus Wellness Ltd operates in the FMCG industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>Zydus Wellness Limited was incorporated on November 1, 1994, originally as 'Carnation Health Foods Limited'. The company underwent several name changes, becoming 'Carnation Nutra-Analogue Foods Limited' before finally adopting its current name on January 5, 2009. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 9,131 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,719 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 12,843 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00 <BR>Industry P/E: 56 <BR>Dividend Yield: 0.55% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 6.02% <BR>Price to Book: 2.26 <BR><BR>Contact Details:<BR>Address: Zydus Corporate Park S No 536, Sarkhej-Gandhinagar Highway Ahmedabad Gujarat : 382481 <BR>Tel: 91-79-67775888 <BR>Email: investor.grievance@zyduswellness.in <BR>Website: http://www.zyduswellness.in

View full answer

Who are the top shareholders of the Zydus Wellness?

17-Jul-2025

The top shareholders of Zydus Wellness include Zydus Lifesciences Limited with 57.59%, Threpsi Care LLP at 7.27%, and individual investors at 5.91%. Mutual funds hold 11.61%, while foreign institutional investors account for 3.29%, with no pledged promoter holdings reported.

The top shareholders of Zydus Wellness include Zydus Lifesciences Limited, which holds the largest stake at 57.59%. Other significant shareholders are Threpsi Care LLP, with a holding of 7.27%, and individual investors, who collectively own 5.91%. Additionally, mutual funds are represented through 13 schemes, accounting for 11.61% of the shares, while foreign institutional investors (FIIs) hold 3.29% through 101 different entities. There are no pledged promoter holdings reported.

View full answer

Is Zydus Wellness technically bullish or bearish?

04-Nov-2025

As of November 3, 2025, the trend is mildly bullish with daily moving averages supporting this view, but mixed signals from the MACD and KST suggest a cautious approach.

As of 3 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, suggesting mixed signals across time frames. Bollinger Bands are bullish on both weekly and monthly charts, reinforcing the positive outlook. However, the KST shows a bullish weekly trend but is mildly bearish monthly, indicating some caution. Overall, while there are bullish indicators, the mixed signals suggest a cautious approach.

View full answer

How has been the historical performance of Zydus Wellness?

06-Nov-2025

Zydus Wellness has shown consistent growth in net sales and profits from March 2020 to March 2025, with net sales increasing from 1,766.82 Cr to 2,708.90 Cr and operating profit peaking at 393.30 Cr, despite some fluctuations in profit margins and cash flow. Total liabilities rose to 6,297.20 Cr, while cash flow from operations improved to 380.00 Cr.

Answer:<BR>The historical performance of Zydus Wellness shows a consistent growth trajectory in net sales and profit over the years, with notable fluctuations in profit margins and cash flow.<BR><BR>Breakdown:<BR>Zydus Wellness has demonstrated significant growth in net sales, increasing from 1,766.82 Cr in March 2020 to 2,708.90 Cr in March 2025. The total operating income has mirrored this growth, reaching 2,708.90 Cr in March 2025, up from 1,766.82 Cr in March 2020. The operating profit (PBDIT) has also shown an upward trend, with a peak of 393.30 Cr in March 2025, although it experienced some fluctuations in previous years. Profit before tax reached 358.80 Cr in March 2025, while profit after tax stood at 346.90 Cr, indicating a healthy profitability despite a slight decline from the previous year. The company’s total liabilities increased to 6,297.20 Cr in March 2025, up from 5,468.89 Cr in March 2020, reflecting a rise in both short-term and long-term borrowings. Cash flow from operating activities improved significantly to 380.00 Cr in March 2025, compared to 259.00 Cr in March 2020, although the net cash outflow was recorded at -13.00 Cr in March 2025. Overall, Zydus Wellness has shown resilience and growth in its financial performance over the years.

View full answer

Is Zydus Wellness overvalued or undervalued?

07-Nov-2025

As of November 6, 2025, Zydus Wellness is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 49.20 and a recent 1-week decline of 8.76%, despite a strong year-to-date return of 14.50%.

As of 6 November 2025, the valuation grade for Zydus Wellness has moved from fair to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 49.20, an EV to EBITDA of 44.54, and a Price to Book Value of 0.25, which suggest that the stock is trading at a premium compared to its earnings and asset value.<BR><BR>In comparison to its peers, Zydus Wellness has a lower PE ratio than Hindustan Unilever, which stands at 54.11, and Nestle India, which has a PE of 81.85. However, the overall valuation of Zydus Wellness remains expensive in the context of the FMCG sector, where many peers are also categorized as very expensive. Despite a strong year-to-date return of 14.50% compared to the Sensex's 6.62%, the stock's recent performance has been lackluster, with a 1-week decline of 8.76%, reinforcing the notion that it may be overvalued at current levels.

View full answer

When is the next results date for Zydus Wellness Ltd?

22-Jan-2026

The next results date for Zydus Wellness Ltd is February 3, 2026.

The next results date for Zydus Wellness Ltd is scheduled for February 3, 2026.

View full answer

Are Zydus Wellness Ltd latest results good or bad?

03-Feb-2026

Zydus Wellness Ltd's latest results show strong revenue growth of 108.90% year-on-year, reaching ₹964.90 crores, but the company reported a net loss of ₹39.90 crores, a significant decline from last year's profit, indicating serious profitability challenges despite increased sales. Investors should be cautious due to rising costs and ongoing financial difficulties.

Zydus Wellness Ltd's latest results present a mixed picture, but overall, they indicate significant challenges. While the company achieved impressive revenue growth of 108.90% year-on-year, reaching ₹964.90 crores, it also reported a net loss of ₹39.90 crores for Q3 FY26, a stark contrast to the profit of ₹6.40 crores in the same quarter last year. This represents a dramatic decline in profitability, with the loss increasing by 723.44% year-on-year.<BR><BR>The operating margin improved slightly to 6.33%, but this is still far below historical levels, indicating that despite strong sales, the company is struggling to convert revenue into profit. The substantial rise in interest costs, which surged by over 1,100% to ₹41.20 crores, has heavily impacted the bottom line, alongside a significant increase in depreciation expenses.<BR><BR>In summary, while Zydus Wellness has demonstrated strong revenue growth, the inability to achieve profitability amidst rising costs and operational challenges suggests that the latest results are more concerning than positive. Investors may need to be cautious given the current financial trajectory and the company's ongoing profitability crisis.

View full answer

Should I buy, sell or hold Zydus Wellness Ltd?

04-Feb-2026

Why is Zydus Wellness Ltd falling/rising?

06-Feb-2026

As of 06-Feb, Zydus Wellness Ltd's stock price is declining, currently at 387.60, with a 4.75 (-1.21%) drop. This decline is due to poor financial performance, reduced investor interest, and consistent losses over recent weeks.

As of 06-Feb, Zydus Wellness Ltd's stock price is falling, currently at 387.60, reflecting a decrease of 4.75 (-1.21%). The stock has been on a downward trend, having lost 13.05% over the past week and 19.01% over the past month. This consistent decline is attributed to several factors. <BR><BR>Firstly, the stock has underperformed its sector by 2.61% today and has experienced six consecutive days of losses. It is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 19.56% compared to the 5-day average.<BR><BR>Financially, the company has faced challenges, including a substantial decline in operating profit of 36.36% and negative results reported for the last two consecutive quarters. The profit after tax for the most recent quarter was reported at Rs -33.30 crore, a drastic fall of 146.3% compared to the previous four-quarter average. Although the company has a strong ability to service its debt, as indicated by a healthy EBIT to Interest ratio of 14.07, the overall poor long-term growth prospects, with net sales growing at an annual rate of only 14.15% and operating profit at 3.21% over the last five years, contribute to the negative sentiment surrounding the stock.<BR><BR>In summary, the combination of declining stock performance, poor financial results, and reduced investor interest has led to the current downward movement in Zydus Wellness Ltd's stock price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Poor long term growth as Net Sales has grown by an annual rate of 14.15% and Operating profit at 3.21% over the last 5 years

 
2

With a fall in Operating Profit of -36.36%, the company declared Very Negative results in Dec 25

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

FMCG

stock-summary
Market cap

INR 12,376 Cr (Small Cap)

stock-summary
P/E

50.00

stock-summary
Industry P/E

52

stock-summary
Dividend Yield

0.31%

stock-summary
Debt Equity

0.51

stock-summary
Return on Equity

5.04%

stock-summary
Price to Book

2.19

Revenue and Profits:
Net Sales:
965 Cr
(Quarterly Results - Dec 2025)
Net Profit:
-40 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.31%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.85%
0%
-12.85%
6 Months
-0.98%
0%
-0.98%
1 Year
8.57%
1.76%
10.33%
2 Years
20.99%
3.44%
24.43%
3 Years
32.19%
5.57%
37.76%
4 Years
15.91%
6.63%
22.54%
5 Years
3.42%
6.89%
10.31%

Latest dividend: 6 per share ex-dividend date: Jul-11-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Zydus Wellness Declines 13.05% Amid Profitability Crisis and Valuation Reassessment

Key Events This Week

2 Feb: Stock opens at Rs.435.00 amid broad market weakness

3 Feb: Quarterly results reveal record sales but sharp profit decline

4 Feb: Valuation metrics reclassified as attractive despite downgrade

6 Feb: Week closes at Rs.387.60, down 13.05%

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Newspaper Publication

04-Feb-2026 | Source : BSE

Newspaper publication regarding unaudited financial results for the quarter and nine months ended on December 31 2025

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

03-Feb-2026 | Source : BSE

Audio recording of the Investor Call on unaudited financial results for the quarter and nine months ended on December 31 2025

Unaudited Financial Results For The Quarter / Nine Months Ended On December 31 2025

03-Feb-2026 | Source : BSE

Unaudited financial results for the quarter / nine months ended on December 31 2025

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Zydus Wellness Ltd has declared 60% dividend, ex-date: 11 Jul 25

stock-summary
SPLITS

Zydus Wellness Ltd has announced 2:10 stock split, ex-date: 18 Sep 25

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
14.15%
EBIT Growth (5y)
3.21%
EBIT to Interest (avg)
14.07
Debt to EBITDA (avg)
1.68
Net Debt to Equity (avg)
0.51
Sales to Capital Employed (avg)
0.40
Tax Ratio
8.61%
Dividend Payout Ratio
11.91%
Pledged Shares
0
Institutional Holding
21.85%
ROCE (avg)
5.87%
ROE (avg)
5.92%

Valuation key factors

Factor
Value
P/E Ratio
50
Industry P/E
52
Price to Book Value
2.16
EV to EBIT
46.85
EV to EBITDA
35.44
EV to Capital Employed
1.77
EV to Sales
4.49
PEG Ratio
NA
Dividend Yield
0.31%
ROCE (Latest)
3.83%
ROE (Latest)
5.04%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 15 Schemes (18.11%)

FIIs

Held by 113 FIIs (3.27%)

Promoter with highest holding

Zydus Lifesciences Limited (57.59%)

Highest Public shareholder

Parag Parikh Flexi Cap Fund (7.27%)

Individual Investors Holdings

6.64%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 48.33% vs -24.44% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 24.43% vs -141.28% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "964.90",
          "val2": "650.50",
          "chgp": "48.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "61.00",
          "val2": "23.00",
          "chgp": "165.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "41.20",
          "val2": "15.70",
          "chgp": "162.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.60",
          "val2": "-34.20",
          "chgp": "80.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.90",
          "val2": "-52.80",
          "chgp": "24.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "6.33%",
          "val2": "3.58%",
          "chgp": "2.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 13.31% vs 16.80% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -55.46% vs 44.97% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,511.40",
          "val2": "1,333.90",
          "chgp": "13.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "178.60",
          "val2": "174.90",
          "chgp": "2.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "18.20",
          "val2": "4.50",
          "chgp": "304.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-34.20",
          "val2": "5.90",
          "chgp": "-679.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "75.10",
          "val2": "168.60",
          "chgp": "-55.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.90%",
          "val2": "13.15%",
          "chgp": "-1.25%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 37.89% vs 16.22% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -79.89% vs 50.09% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,476.30",
          "val2": "1,795.80",
          "chgp": "37.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "239.60",
          "val2": "189.70",
          "chgp": "26.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "59.40",
          "val2": "7.80",
          "chgp": "661.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-40.80",
          "val2": "5.90",
          "chgp": "-791.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "35.20",
          "val2": "175.00",
          "chgp": "-79.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.68%",
          "val2": "10.56%",
          "chgp": "-0.88%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 16.37% vs 3.24% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 29.97% vs -14.01% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,708.90",
          "val2": "2,327.80",
          "chgp": "16.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "379.70",
          "val2": "308.20",
          "chgp": "23.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "12.00",
          "val2": "24.00",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.90",
          "val2": "-14.20",
          "chgp": "141.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "346.90",
          "val2": "266.90",
          "chgp": "29.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.11%",
          "val2": "13.31%",
          "chgp": "0.80%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
964.90
650.50
48.33%
Operating Profit (PBDIT) excl Other Income
61.00
23.00
165.22%
Interest
41.20
15.70
162.42%
Exceptional Items
-6.60
-34.20
80.70%
Consolidate Net Profit
-39.90
-52.80
24.43%
Operating Profit Margin (Excl OI)
6.33%
3.58%
2.75%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 48.33% vs -24.44% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 24.43% vs -141.28% in Sep 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
1,511.40
1,333.90
13.31%
Operating Profit (PBDIT) excl Other Income
178.60
174.90
2.12%
Interest
18.20
4.50
304.44%
Exceptional Items
-34.20
5.90
-679.66%
Consolidate Net Profit
75.10
168.60
-55.46%
Operating Profit Margin (Excl OI)
11.90%
13.15%
-1.25%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 13.31% vs 16.80% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is -55.46% vs 44.97% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
2,476.30
1,795.80
37.89%
Operating Profit (PBDIT) excl Other Income
239.60
189.70
26.30%
Interest
59.40
7.80
661.54%
Exceptional Items
-40.80
5.90
-791.53%
Consolidate Net Profit
35.20
175.00
-79.89%
Operating Profit Margin (Excl OI)
9.68%
10.56%
-0.88%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 37.89% vs 16.22% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is -79.89% vs 50.09% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
2,708.90
2,327.80
16.37%
Operating Profit (PBDIT) excl Other Income
379.70
308.20
23.20%
Interest
12.00
24.00
-50.00%
Exceptional Items
5.90
-14.20
141.55%
Consolidate Net Profit
346.90
266.90
29.97%
Operating Profit Margin (Excl OI)
14.11%
13.31%
0.80%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 16.37% vs 3.24% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 29.97% vs -14.01% in Mar 2024

stock-summaryCompany CV
About Zydus Wellness Ltd stock-summary
stock-summary
Zydus Wellness Ltd
Small Cap
FMCG
Zydus Wellness Limited was incorporated on November 1, 1994 as a public limited company with the name 'Carnation Health Foods Limited'. The Company's name was changed from Carnation Health Foods Limited' to Carnation Nutra-Analogue Foods Limited and thereafter from Carnation Nutra-Analogue Foods Limited to Zydus Wellness Limited on January 5, 2009.
Company Coordinates stock-summary
Company Details
Zydus Corporate Park S No 536, Sarkhej-Gandhinagar Highway Ahmedabad Gujarat : 382481
stock-summary
Tel: 91-79-67775888
stock-summary
investor.grievance@zyduswellness.in
Registrar Details
Link Intime India Pvt Ltd., UnitNo. 303, 3rd Floor, Shoppers Plaza V, Opp. Municipal Market, B/h. Shoppers Plaza II, Off. C. G. Road,, Ahmedabad